

**S4 Table. Mean Hb (g/dL) and Mean PLT (K/ $\mu$ L) at Baseline and End of Treatment Stratified by ITPase Functional Activity and Treatment Arm (+RBV/Placebo for RBV)**

<b>ITPase functional activity</b>	<b>Arm</b>	<b>Number</b>	<b>Mean Hb at Baseline <math>\pm</math> SD (g/dL)</b>	<b>Mean Hb at EOT <math>\pm</math> SD (g/dL)</b>	<b>Mean PLT at Baseline <math>\pm</math> SD (K/<math>\mu</math>L)</b>	<b>Mean PLT at EOT <math>\pm</math> SD (K/<math>\mu</math>L)</b>
100 %	+RBV	41	14.59 $\pm$ 1.28	12.22 $\pm$ 1.21	233.5 $\pm$ 56.65	249.3 $\pm$ 56.65
	Placebo	93	14.51 $\pm$ 1.43	13.98 $\pm$ 1.44	235.8 $\pm$ 65.58	234.5 $\pm$ 67.72
60%	+RBV	14	15.12 $\pm$ 1.53	13.15 $\pm$ 1.92	210.0 $\pm$ 33.29	241.9 $\pm$ 52.36
	Placebo	36	14.93 $\pm$ 1.22	14.20 $\pm$ 1.25	220.7 $\pm$ 55.26	209.4 $\pm$ 51.18
25-30%	+RBV	12	14.18 $\pm$ 1.40	13.35 $\pm$ 1.39	213.1 $\pm$ 53.14	248.3 $\pm$ 74.64
	Placebo	20	15.49 $\pm$ 1.51	14.67 $\pm$ 1.40	230.3 $\pm$ 44.14	227.6 $\pm$ 46.54
$\leq$ 10%	+RBV	1	15.00	12.9	237.0	209.0
	Placebo	7	15.06 $\pm$ 1.47	14.69 $\pm$ 1.21	242.0 $\pm$ 112.3	234.7 $\pm$ 96.47